Skip to main content

Table 3 Parameters evaluated at central precocious puberty diagnosis and at follow-up according to the later diagnosis of polycystic ovarian syndrome (PCOS)

From: Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study

Parameter PCOS
N = 10
No PCOS
N = 41
P value
Age at CPP diagnosis (years) 8.1 ± 1.2 (6.8–10.0) 8.5 ± 1.0 (5.7–10.6) 0.360
Bone age at CPP diagnosis (years) 10.1 ± 1.8 (7.1–12.0) 10.2 ± 1.8 (7.1–13.0) 0.982
Advanced over chronological age (months) 21.0 ± 17.3 (5.0–50.0) 18.7 ± 10.9 (0–43.0) 0.928
BMI percentile at CPP diagnosis 83.5 ± 11.1 (65.0–95.0) 76.8 ± 23.9 (1.0–98.9) 0.988
Fetal    0.151
 Appropriate for gestational age 9 (90.0) 36 (87.8)  
 Small for gestational age 0 5 (12.2)  
 Large for gestational age 1 (10.0) 0  
Prematurity (< 37 weeks) 1 (10.0) 4 (9.8) 1.00
Clinical presentation at CPP diagnosis    0.367
 Pubarche and thelarche 5 (50.0) 26 (70.3)  
 Thelarche 3 (30.0) 7 (18.9)  
 Pubarche 2 (20.0) 4 (10.8)  
LH at CPP diagnosis (IU/L) 2.1 ± 1.9 (0.1–6.0) 2.0 ± 1.5 (0.1–6.2) 0.925
FSH at CPP diagnosis (IU/L) 4.0 ± 2.4 (1.40–8.3) 4.3 ± 2.1 (1.1–9.4) 0.625
Estradiol at CPP diagnosis (pmol/L) 203.3 ± 160.5 (70–518) 150.0 ± 193.7 (70–1080) 0.140
LH/FSH ratio at CPP diagnosis 0.6 ± 0.3 (0.1–1.0) 0.5 ± 0.3 (0.1–1.4) 0.479
GnRH analogue treatment for CPP 6 (60.0) 21 (51.2) 0.735
  1. Data presented as Mean ± SD or n (%)
  2. Note: LH Luteinizing Hormone, FSH Follicle Stimulating Hormone, BMI Body Mass Index, GnRH Gonadotropin releasing hormone